title: Phase II clinical study on the GEMOX regimen as second- line therapy for advanced ovarian cancer.
abstract: OBJECTIVE
  To investigate the effectiveness and adverse effects of gemcitabine by fixed-dose rate infusion plus oxaliplatin (GEMOX regimen) as second-line therapy for advanced ovarian cancer.
  
  
  METHODS
  64 patients with advanced ovarian cancer were divided into an experimental group (44 cases) and a control group (20 cases). The experimental group was treated with continuous intravenous infusion of gemcitabine at 1000 mg/m(2) with a fixed-dose rate of 10 mg/m(2)/min, on days 1 and 8 and oxaliplatin at 100 mg/m(2) on day 1, IVGTT, repeated every 3 weeks. The control group was treated with intravenous infusion of gemcitabine at 1000 mg/m(2) within 30 min on days 1 and and oxaliplatin at 100 mg/m(2) on day 1, IVGTT, again repeated every 3 weeks. CT scans or MRI were used for review every 1-2 cycles.
  
  
  RESULTS
  The effective rate in the experimental group was significantly high than control group (43.2% vs 35.0%; P < 0.05), with no obvious difference of hematologic or non-hematologic toxicity between the two groups (P > 0.05).
  
  
  CONCLUSIONS
  GEMOX regimen is very effective to treat advanced ovarian cancer, with low toxicity, good tolerance and improved life quality in patients.
authors.affiliation: Department of Oncology and Chemoradiotherapy of Rui'an People Hospital, Wenzhou, Zhejiang, China.
authors.forename: Shao-Fei
authors.initials: SF
authors.lastname: Yuan
authors.forename: Lian-Ping
authors.initials: LP
authors.lastname: Zhang
authors.forename: Lin-Jia
authors.initials: LJ
authors.lastname: Zhu
authors.forename: Wen-Jun
authors.initials: WJ
authors.lastname: Chen
authors.forename: Wei-E
authors.initials: WE
authors.lastname: Zheng
authors.forename: Jian-Ping
authors.initials: JP
authors.lastname: Xiong
mesh_terms: D018262:Adenocarcinoma, Clear Cell / Q000188:drug therapy / Q000401:mortality* / Q000473:pathology; D002288:Adenocarcinoma, Mucinous / Q000188:drug therapy / Q000401:mortality* / Q000473:pathology; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016022:Case-Control Studies; D018284:Cystadenocarcinoma, Serous / Q000188:drug therapy / Q000401:mortality* / Q000473:pathology; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016889:Endometrial Neoplasms / Q000188:drug therapy / Q000401:mortality* / Q000473:pathology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D009944:Organoplatinum Compounds / Q000627:therapeutic use; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000401:mortality* / Q000473:pathology; D011379:Prognosis; D011788:Quality of Life; D015996:Survival Rate
chemical_list: D009944:Organoplatinum Compounds; D003841:Deoxycytidine